Mentions in press and media 18
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Dec 18, 2025 | PRISM BioLab and Talus Bioscience Join Forces to Discover Novel Inhibitors of Transcription Factor and Protein-Protein Interaction Targets | TOKYO, Dec. 18, 2025 /PRNewswire/ -- PRISM BioLab, Co. Ltd. ("PRISM") and Talus Bioscience, Inc. ("Talus Bio") announced today that they entered into a collaboration to discover novel Inhibitors of transcription factor (... |
| Nov 14, 2025 | PRISM BioLab Achieved Initial Milestone and Receives the Milestone Payment in Drug Discovery Collaboration with Ono Pharmaceutical Co., Ltd. | TOKYO, Nov. 14, 2025 /PRNewswire/ -- PRISM BioLab, Co. Ltd. ("PRISM") announces that today, PRISM and Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka; President and COO: Toichi Takino; hereinafter "Ono") have achieved ... |
| May 23, 2025 | Innovations in Oncology: A Look Ahead to ASCO 2025 | The American Society of Clinical Oncology (ASCO) Annual Meeting is a beacon for cancer research. This year, it shines brightly in Chicago from May 30 to June 3, 2025. The event promises a treasure trove of insights into groundbreaking thera... |
| May 23, 2025 | Eisai to Present E7386, Co-created by PRISM BioLab and Eisai, at the ASCO (American Society of Clinical Oncology) Annual Meeting | Abstract Released for E7386, Co-Developed Through Collaborative Research Between Eisai and PRISM TOKYO, May 23, 2025 /PRNewswire/ -- PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery and development biotechnology company desig... |
| Apr 15, 2025 | The Future of Drug Development: A New Era of Innovation and Collaboration | In the world of pharmaceuticals, innovation is the lifeblood. The landscape is shifting, driven by collaboration and cutting-edge technology. Two recent developments illustrate this trend: the European Commission's impending decision on lec... |
| Apr 14, 2025 | PRISM BioLab and Elix Join Forces to Accelerate AI-Driven Drug Discovery for Protein-Protein Interaction Targets | Strategic Partnership Aims to Create Novel Drug Discovery Pipeline for Unmet Medical Needs by Combining PPI Control Technology with AI Drug Discovery Platform TOKYO, April 14, 2025 /PRNewswire/ -- PRISM BioLab, Co. Ltd. ("PRISM BioLab&... |
| Sep 9, 2024 | PRISM BioLab Co., Ltd. Eisai made a presentation at the ESMO (European Society of Medical Oncology) annual general meeting regarding E7386, a jointly created product between our company and Eisai. | |
| Apr 25, 2024 | PRISM BioLab, enters into a Joint Research and Licensing Agreement with Ono | PRISM BioLab will utilize PepMetics®, innovative small molecules that mimic three-dimensional structures of alpha-helix and beta-turns of peptides for drug discovery against oncology target selected by Ono TOKYO, April 25, 2024 /PRNewswire/... |
| Jan 26, 2024 | PRISM BioLab Raises 1.5 Billion Yen in Series C Funding | PRISM BioLab, a Tokyo, Japan-based discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, raised 1.5 Billion Yen ($10.3M) in Series C funding. The round saw particip... |
Show more
Reviews 0
FAQ about PRISM BioLab
What has the press written about PRISM BioLab?
Parsers VC has collected 18 articles mentioning PRISM BioLab, among them “PRISM BioLab and Talus Bioscience Join Forces to Discover Novel Inhibitors of Transcription Factor and Protein-Protein Interaction Targets” (Dec 18, 2025) and “PRISM BioLab Achieved Initial Milestone and Receives the Milestone Payment in Drug Discovery Collaboration with Ono Pharmaceutical Co., Ltd.” (Nov 14, 2025).
Is PRISM BioLab still active?
Yes, PRISM BioLab is active; its latest activity on Parsers VC dates from Mar 13, 2026.